Physician profile
Brandon Baker
NPI 1528450665
$1,970.03
in general payments reported to CMS, 2019-2025
16 companies · $23.19 in 2025
The $23.19 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $624 · 2021: $140 · 2023: $19.26 · 2025: $23.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $436.29 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $422.18 | 2019-2020 | |
| Allergan, INC. | $375.31 | 2019-2020 | |
| Neos Therapeutics, LP | $162.64 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $120.80 | 2019 | |
| Lundbeck LLC | $83.27 | 2019-2020 | |
| Shire North American Group INC | $81.40 | 2019 | |
| Ironshore Pharmaceuticals INC. | $76.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $54.66 | 2019 | |
| Alkermes, INC. | $43.78 | 2019 | |
| Abbvie INC. | $23.19 | 2025 | |
| Tris Pharma INC | $21.18 | 2019 | |
| Corium, LLC | $19.26 | 2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $18.18 | 2019 | |
| Adlon Therapeutics L.P. | $16.47 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.